drugset / Trial / NCT04698642
A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat
RandomizedParallel-groupOpen-labelTreatment
Summary
The Phase 2a component of the study will be a randomized, open-label, parallel, and multiple dose study to further examine the safety and efficacy profile of 3 CBL-514 dose levels based on the results from Phase 1 of the study.
Timeline
- Start
- 2020-02-03
- Primary completion
- 2020-11-12
- Completion
- 2020-11-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CBL-514 | Unknown | 180 mg | — |
| Subject | CBL-514 | Unknown | 240 mg | — |
| Subject | CBL-514 | Unknown | 300 mg | — |
Indications
No indication recorded.